Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel
anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic
asthma and the related increased sensitivity of the airways to other substances, as well as
to investigate a possible anti-inflammatory effect of the drug in the airways.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.